NSCLC
Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance.
Human non-small cell lung cancers (<span class="disease" id="22751098-1-35-40">NSCLC</span>s) with activating mutations in <span class="gene" id="22751098-1-72-76">EGFR</span> frequently respond to treatment with <span class="gene" id="22751098-1-114-118">EGFR</span>-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance.